Stock Ratings / Health Care / AURA / financials

SLBT (47) DBVT (26) CADL (38) IAM (50) ⌘ Pro Terminal →

Aura Biosciences Inc. (AURA) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$6.30 -1.64% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.27

Aura Biosciences Inc. (AURA) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $652.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $6.27 (-0.49%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-8.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AURA)Realized 20D OHLCV Swing Band: ±9.9%

Deterministic 5-Pillar Attribution (40/100 Composite)

🔍 WHY AURA SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+12/20 pts (30% of score)

FRED Regime × Technicals: 33% of 52W Range • RSI-14 at 42.6 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$6.54-6.7% Next Q

Q2 (-2Q)

Grade D$6.10+3.3% Next Q

Q3 (-1Q)

Grade D$6.30+0% Next Q

Current

Grade D-$6.30-7.4% Hist 90D α

Trajectory: D (48) → D- (40)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AURA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AURA currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.68) and Max Pain ($6.62) forces dealer call-delta covering toward $10.02.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AURA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “AURA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 40%NO 60%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How AURA Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-2.8%	-$106.2M	-$85.2M	-45%
FY 2024	$4.00B	52%	-2.4%	-$86.9M	-$81.1M	-45%
FY 2023	$4.00B	52%	-2.1%	-$76.4M	-$63.8M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AURA)

✓Walkthrough of AURA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AURA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -10.64%▼ DESCENDING CHANNEL

2026-10-30O $6.30H $6.43L $6.03C $6.30VOL 533.0K

RES: $7.56SUP: $5.35SMA50: $6.68SMA200: $6.72

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AURA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AURA Butterfly Map → + Track AURA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AURA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AURA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AURA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AURA)

Health Care Rank #634 of 1016 ⚔️ SLBT vs AURA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AURA vs. SLBT, DBVT, CADL, IAM)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Aura Biosciences Inc. (AURA) ranks #634 by composite RQD confidence (40/100, grade D-) and #411 by equity capitalization ($652.8M). Within this direct 5-issuer industry benchmark cohort, AURA leads on earnings valuation at N/A trailing P/E, while AURA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IAM currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with AURA at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AURA ACTIVE Aura Biosciences Inc.	D-	40/100	—	—	-35.0%	-1.64%	$652.8M	Benchmark Subject
SLBT SL Science Holding Limited	D	47/100	—	—	—	-3.31%	$656.1M	/slbt-vs-aura →
DBVT DBV Technologies S.A.	E	26/100	—	—	-35.0%	-3.38%	$647.0M	/dbvt-vs-aura →
CADL Candel Therapeutics Inc.	D-	38/100	—	—	-35.0%	-0.23%	$661.9M	/cadl-vs-aura →
IAM Iambic Therapeutics Inc.	D	50/100	—	—	—	-3.38%	$676.9M	/iam-vs-aura →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001501796

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aura Biosciences Inc. (AURA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$106.2M, operating cash flow of -$84.7M, and free cash flow of -$85.2M (-5.1% YoY). On the balance sheet, AURA closed FY2025 with $169.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$106.2M	-$84.7M	-$85.2M	$169.4M	—
FY2024 (FY)	2024-12-31	$0	-$86.9M	-$79.8M	-$81.1M	$182.5M	—
FY2023 (FY)	2023-12-31	$0	-$76.4M	-$63.8M	-$63.8M	—	—

3. AURA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AURA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Aura Biosciences Inc. (NASDAQ: AURA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $6.30 (-1.64% 1D, market cap $652.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AURA ranks #634 in composite RQD confidence.

How does AURA compare to SLBT and DBVT in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), AURA carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SLBT (SL Science Holding Limited) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $656.1M) and DBVT (DBV Technologies S.A.) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $647.0M). Among the 5-stock peer group, AURA leads on earnings multiple (N/A) while AURA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AURA?

Per AURA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001501796), Aura Biosciences Inc. generated $0 in revenue, -$106.2M in net income, and -$85.2M in free cash flow against $169.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AURA trading relative to its 50-day, 200-day, and 52-week technical levels?

AURA last traded at $6.30 (-1.64% on volume of 769,981 shares), positioning the stock -5.69% below its 50-day simple moving average ($6.68) and -6.25% below its 200-day simple moving average ($6.72). Across its 52-week range of $4.73 to $9.54, AURA sits at the 32.6% percentile with a 14-day RSI of 42.6 (NEUTRAL RANGE) and an implied next-earnings move of ±9.9% ($5.68 to $6.92).

AURA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Aura Biosciences Inc. (AURA)?

In FY 2025 (10-K), AURA converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: AURA RQD Cockpit AURA 12M Forecast AURA Earnings & Move AURA Dividends & DRIP AURA Insiders & 13F AURA Whale Options AURA Profit Sankey AURA News & Why